Newsroom

Biotechnology

Explore the latest breakthroughs and trends in the Biotechnology sector with our newsroom. From cutting-edge innovations in gene therapy and biopharmaceuticals to advancements in medical research and regulatory updates, we provide essential insights into the scientific developments shaping the future of healthcare and life sciences.


Latest Press Releases

Molecular Partners Reports Key Financials for FY 2019 and Corporate Highlights from Q4 2019
BiotechnologyEarnings

Molecular Partners Reports Key Financials for FY 2019 and Corporate Highlights from Q4 2019

February 6, 2020 1:00 AM

Research & Development: Abicipar in Neovascular Wet Age-Related Macular Degeneration: Two-year results from CEDAR and SEQUOIA presented at AAO in October 2019 demonstrate that vision gains observed after one year with both, every 8-week and every 12-week dosing were maintained in second year FDA and EMA filings accepted and under review MP0250 (VEGF x HGF) in Multiple Myeloma: Updated data presented at ASH in...

Read more
Dyadic to Present at Two Upcoming Conferences
BiotechnologyCompany UpdateConferences

Dyadic to Present at Two Upcoming Conferences

February 5, 2020 4:15 PM

JUPITER, FL / ACCESSWIRE / February 5, 2020 / Dyadic International, Inc. (the "Company") (NASDAQ:DYAI), today announced that its President and Chief Executive Officer, Mark Emalfarb, will be presenting at the following investor conferences: BIO CEO & Investor Conference Marriott Marquis New York City, NY Monday, February 10, 2020 2:15 p.m. ET NobleCon16 Seminole Hard Rock Hotel & Casino Hollywood, FL Monday, February 17, 2020 2:30 p.m. ET...

Read more
Players Network, Inc. Shareholder 2019 Year in Review and 2020 Outlook
BiotechnologyCompany Update

Players Network, Inc. Shareholder 2019 Year in Review and 2020 Outlook

February 5, 2020 8:05 AM

Green Leaf Farms International is Raising Capital in Their Founders Round. LAS VEGAS, NV / ACCESSWIRE / February 5, 2020 / Player's Network, Inc. (OTCPINK:PNTV), a rapidly growing international company in the adult-use and medical marijuana industry, with operations in Las Vegas, Nevada and Jujuy Argentina, published a Shareholder update from CEO Mark Bradley. Please visit this link https://playersnetwork.com/2019-year-in-review/ to view...

Read more
Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020
BiotechnologyCompany Update

Dyadic to Interview with Bloomberg TV on Friday, January 31, 2020

January 31, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / January 31, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more
Mota Ventures Recap of First Class Conference Call
BiotechnologyCompany Update

Mota Ventures Recap of First Class Conference Call

January 30, 2020 8:00 AM

VANCOUVER, BC / ACCESSWIRE / January 30, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company") would like to thank all shareholders and investors for attending yesterday's conference call. The main items addressed on the call were the revenue, profit margins and the short- and long-term growth plans of First Class CBD ("First Class"), a wholly owned subsidiary of the Company. The conference call will be available for...

Read more
Dyadic Interviewed with FOX Business Network
BiotechnologyCompany Update

Dyadic Interviewed with FOX Business Network

January 28, 2020 9:50 AM

JUPITER, FL / ACCESSWIRE / January 28, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more
1933 Industries Engages Market Makers
BiotechnologyCompany Update

1933 Industries Engages Market Makers

January 27, 2020 10:00 PM

VANCOUVER, BC / ACCESSWIRE / January 27, 2020 / 1933 Industries Inc. (the "Company" or "1933 Industries") (CSE:TGIF)(OTCQX:TGIFF), a vertically-integrated and growth-orientated cannabis consumer packaged goods company, announces that it has retained the services of PI Financial Corp. ("PI") and Independent Trading Group ("ITG") for market making services in accordance with the Canadian Securities Exchange policies. For the purposes of...

Read more
Dyadic to Interview with FOX Business Network on Monday, January 27, 2020
BiotechnologyCompany Update

Dyadic to Interview with FOX Business Network on Monday, January 27, 2020

January 27, 2020 8:00 AM

JUPITER, FL / ACCESSWIRE / January 27, 2020 / Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to accelerate development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief...

Read more
Having trouble sleeping? cbdMD has you covered
BiotechnologyAdvertorial

Having trouble sleeping? cbdMD has you covered

January 24, 2020 7:50 PM

NEW YORK, NY / ACCESSWIRE / January 24, 2020 / Everyday we face a lot of stress and tension that it causes most of us to have a week or worse, a month of sleepless nights. All that tossing, turning, and staring at the ceiling almost every night can leave you feeling more tired and stressed the next day. It's estimated that 70 million people in the U.S. suffer from some form of sleeplessness. If you're one of those who's caught in this...

Read more
Mota Ventures Forms Research and Development Partnership with Leading Colombian University & Research Hospital
BiotechnologyCompany UpdatePartnerships

Mota Ventures Forms Research and Development Partnership with Leading Colombian University & Research Hospital

January 23, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / January 23, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company") is pleased to announce that its wholly owned subsidiary Ihuana S.A.S ("Ihuana") has entered into a research cooperation agreement (the "Agreement") with La Fundacion Universitaria de Ciencias de la Salud (The University Foundation of Health Sciences) (the "University") located in Bogota, Colombia. Pursuant to the Agreement, the...

Read more
Experion Signs Non-Binding Term Sheet for Up To $8.5 Million Term Loan from Trichome Financial, a Leading Cannabis Focused Institutional Investor
BiotechnologyCompany Update

Experion Signs Non-Binding Term Sheet for Up To $8.5 Million Term Loan from Trichome Financial, a Leading Cannabis Focused Institutional Investor

January 22, 2020 8:45 AM

Debt Funding Targeted at Accelerating Growth and Capacity Expansion Initiatives VANCOUVER, BC / ACCESSWIRE / January 22, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) is pleased to announce that it has signed a non-binding term sheet (the "Term Sheet") to receive up to $8.5 million in the form of a senior secured term loan (the "Term Loan") from Trichome Financial Corp. ("Trichome...

Read more
Experion Announces Returning Board Director
BiotechnologyCompany UpdateManagement Changes

Experion Announces Returning Board Director

January 21, 2020 8:45 AM

VANCOUVER, BC / ACCESSWIRE / January 21, 2020 / Experion Holdings Ltd. (the "Company" or "Experion") (TSXV:EXP)(OTCQB:EXPFF)(FRANKFURT:MB31) today announces the return of Sean MacNeil as director effective January 17, 2020. Mr. MacNeil took a leave from the Board early last summer to help his wife, Terri, work through her latest cancer treatment. With the support of Terri and his family, Mr. MacNeil has rejoined the Board to provide his...

Read more
Mota Schedules Investor Conference Call with First Class CBD Management
BiotechnologyCompany Update

Mota Schedules Investor Conference Call with First Class CBD Management

January 21, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / JANUARY 21, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company" or "Mota Ventures") an emerging vertically integrated global CBD brand, is pleased to announce that due to the high volume of questions resulting from the Monday, January 20, 2020 investor conference call, the Company will host a follow-up investor conference call on January 29, 2020 at 1:15 pm (Vancouver time). The follow-up...

Read more
Mota Schedules Investor Call Due to Volume of Inquiries
BiotechnologyCompany Update

Mota Schedules Investor Call Due to Volume of Inquiries

January 15, 2020 3:05 AM

VANCOUVER, BC / ACCESSWIRE / January 15, 2020 / MOTA VENTURES CORP. (CSE:MOTA)(FSE:1WZ:GR)(OTC:PEMTF) (the "Company" or "Mota Ventures") an emerging vertically integrated global CBD brand, is pleased to announce it will be hosting an investor conference call. Due to the significant number of inquiries from investors, Mota will be discussing recent announcements. The conference call will be held on Monday, January 20, 2020 at 1:15PM PST/4:15PM...

Read more
Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology
BiotechnologyCompany Update

Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology

January 14, 2020 8:35 AM

- SHP656 program utilized Xenetic's PolyXen platform technology to conjugate polysialic acid to therapeutic blood-clotting factors - Phase 1/2 study demonstrated SHP656's efficacy and pharmacokinetic data commensurate with the profile of an extended half-life rFVIII product FRAMINGHAM, MA / ACCESSWIRE / January 14, 2020 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing...

Read more
Interface Biologics Announces Spinout, Ripple Therapeutics
BiotechnologyCompany Update

Interface Biologics Announces Spinout, Ripple Therapeutics

January 14, 2020 8:00 AM

TORONTO, ON / ACCESSWIRE / January 14, 2020 / Following the sale of its surface modification business to Evonik (EVR:ETK), Interface Biologics Inc. ("IBI"), is pleased to announce the launch of Ripple Therapeutics Corporation ("Ripple"), a privately held, clinical stage developer of novel drugs. The Ripple Epidel technology is founded on a discovery that drugs can be engineered into controlled release Pharmaceuticals and Medical Device...

Read more
Cutting Edge Immunotherapy for Peanut Allergy Presented at Biotech Showcase(TM) 2020
BiotechnologyCompany UpdateConferences

Cutting Edge Immunotherapy for Peanut Allergy Presented at Biotech Showcase(TM) 2020

January 13, 2020 1:30 PM

SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2020 / Intrommune Therapeutics presented an update today on their oral mucosal immunotherapy (OMIT) technology at the Biotech Showcase™, which occurs during the annual J.P. Morgan Healthcare Conference. To view the full interactive, multimedia news release, click here. "We are very excited to provide investors an overview of our OMIT technology," said Michael Nelson, CEO, Intrommune...

Read more
A New Prescription Nasal Spray Providing Hope to Dementia Patients and their Carers
BiotechnologyConferences

A New Prescription Nasal Spray Providing Hope to Dementia Patients and their Carers

January 9, 2020 9:05 AM

Presenting at Sachs 3rd Neurosciences Innovation Forum Sunday, January 12, 2020 at 12:05 PM Marines' Memorial Club in San Francisco, California Presenting at Biotech Showcase Tuesday January 14, 2020 9:30 AM Hilton San Francisco Union Square in San Francisco, California. SAN FRANCISCO, CA / ACCESSWIRE / January 9, 2020 / LACHESIS BIOSCIENCES LTD, a clinical-stage biotechnology company targeting dementia caused by Alzheimer's and...

Read more
Pacylex Discusses new oncology target and drug candidate at Biotech Showcase: PCLX-001 is getting ready to enter clinical trials
BiotechnologyConferences

Pacylex Discusses new oncology target and drug candidate at Biotech Showcase: PCLX-001 is getting ready to enter clinical trials

January 9, 2020 9:05 AM

Presenting at the Biotech Showcase Monday, January 13, 2020, 4 pm PST at the Hilton San Francisco Union Square in San Francisco, California. EDMENTON, ALBERTA / ACCESSWIRE / January 9, 2020 / PACYLEX PHARMACEUTICALS, INC. a pre-IND-stage pharmaceutical company targeting hematologic cancers with a new first-in-class therapeutic, announced today that its chief executive officer, Michael Weickert, will present at the Biotech Showcase 2020...

Read more
PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive Officer, Alexander Belcredi, will present at the Biotech Showcase 2020 Conference
BiotechnologyConferences

PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive Officer, Alexander Belcredi, will present at the Biotech Showcase 2020 Conference

January 8, 2020 5:35 PM

Presenting at the Biotech Showcase, 2020 Tuesday, January 14, 2020 10:30 am PST PhagoMed's presentation at Biotech Showcase will cover its proprietary engineering platform, its lead assets and an outlook to the plans for 2020 and beyond VIENNA / ACCESSWIRE / January 8, 2020 / PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings, announced...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
What does Meltwater cost in 2026, and what are the alternatives? Meltwater resells press release dis
By Jennifer Hammers • June 22, 2026
What does Meltwater cost in 2026, and what are the alternatives? See how ACCESS Newswire compares on distribution, data, and price.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?